Pembrolizumab + Vismodegib
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Basal Cell Carcinoma
Conditions
Skin Basal Cell Carcinoma
Trial Timeline
Feb 1, 2016 → Aug 29, 2018
NCT ID
NCT02690948About Pembrolizumab + Vismodegib
Pembrolizumab + Vismodegib is a phase 1/2 stage product being developed by Merck for Skin Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02690948. Target conditions include Skin Basal Cell Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Skin Basal Cell Carcinoma were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02690948 | Phase 1/2 | Completed |
Competing Products
20 competing products in Skin Basal Cell Carcinoma